US2017224742A1PendingUtilityA1

Phospholipid-containing marine extracts for treatment of cardiovascular diseases

Assignee: NEPTUNE TECH & BIORESSOURCES INCPriority: Jun 18, 2001Filed: Sep 16, 2016Published: Aug 10, 2017
Est. expiryJun 18, 2021(expired)· nominal 20-yr term from priority
Inventors:Tina Sampalis
A61P 5/24A61P 9/10A61P 9/00A61P 9/06A61P 7/02A61P 37/06A61P 3/08A61P 9/12A61P 3/06A61P 35/00A61P 29/00A61P 3/10A61K 31/683A61P 15/00A61K 31/23A61K 31/20A61K 31/355A61P 15/08A61K 31/232A61P 19/02A61K 33/00A61K 35/612A61P 17/00A61K 31/202A61K 9/0053A61K 31/575A61K 31/685A61K 31/122A61K 31/688A61K 31/015A61K 31/07A61P 17/02A61K 31/201A61K 9/48A61K 33/30
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a method of treatment and/or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and/or marine oil to a patient. The present invention also relates to a composition for the treatment and/or prevention of these diseases.

Claims

exact text as granted — not AI-modified
1 .- 57 . (canceled) 
     
     
         58 . A method of simultaneously decreasing triglyceride and low-density lipoprotein (LDL) levels in a human, comprising administering to a human in need thereof an amount of a krill extract effective to decrease triglyceride and low-density lipoprotein (LDL) levels in a human, wherein the krill extract comprises eicosapentanoic acid and docosahexanoic acid. 
     
     
         59 . The method of  claim 58 , wherein the triglyceride levels are decreased by about 15% and the LDL levels are decreased by about 13%. 
     
     
         60 . The method of  claim 58 , wherein the administering is effected orally. 
     
     
         61 . The method of  claim 60 , wherein the krill extract is contained in a capsule. 
     
     
         62 . The method of  claim 61 , wherein the krill extract is administered daily. 
     
     
         63 . The method of  claim 62 , wherein the krill extract is administered at a dose of 1 to 4.8 g. 
     
     
         64 . The method of  claim 58 , wherein the krill extract is an oil extract free of enzyme. 
     
     
         65 . The method of  claim 58 , wherein the krill extract comprises more than 30 g/100 g omega-3 lipids. 
     
     
         66 . A method of simultaneously decreasing triglyceride and low-density lipoprotein (LDL) levels and increasing high-density lipoprotein (HDL) levels in a human, comprising administering to a human in need thereof an amount of a krill extract effective to decrease triglyceride and low-density lipoprotein (LDL) levels and increase high-density lipoprotein (HDL) levels in a human, wherein the krill extract comprises eicosapentanoic acid and docosahexanoic acid. 
     
     
         67 . The method of  claim 66 , wherein the triglyceride levels are decreased by about 15%, the LDL levels are decreased by about 13%, and the HDL levels are increased by about 8%. 
     
     
         68 . The method of  claim 66 , wherein the administering is effected orally. 
     
     
         69 . The method of  claim 68 , wherein the krill extract is contained in a capsule. 
     
     
         70 . The method of  claim 69 , wherein the krill extract is administered daily. 
     
     
         71 . The method of  claim 70 , wherein the krill extract is administered at a dose of 1 to 4.8 g. 
     
     
         72 . The method of  claim 66 , wherein the krill extract is an oil extract free of enzyme. 
     
     
         73 . The method of  claim 66 , wherein the krill extract comprises more than 30 g/100 g omega-3 lipids. 
     
     
         74 . A method of simultaneously decreasing triglyceride and low-density lipoprotein (LDL) levels, increasing high-density lipoprotein (HDL) levels, and controlling blood glucose level in a human, comprising administering to a human in need thereof an amount of a krill extract effective to decrease triglyceride and low-density lipoprotein (LDL) levels, increase high-density lipoprotein (HDL) levels, and control blood glucose level in a human, wherein the krill extract comprises eicosapentanoic acid and docosahexanoic acid. 
     
     
         75 . The method of  claim 74 , wherein the triglyceride levels are decreased by about 15%, the LDL levels are decreased by about 13%, the HDL levels are increased by about 8%, and the blood glucose levels are decreased by about 20%. 
     
     
         76 . The method of  claim 74 , wherein the administering is effected orally. 
     
     
         77 . The method of  claim 76 , wherein the krill extract is contained in a capsule.

Join the waitlist — get patent alerts

Track US2017224742A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.